Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation.

Kayson E, Eberly S, Anderson KE, Marder K, Shoulson I, Oakes D, Young AB, Biglan K, Hersch S; Huntington Study Group PHAROS Investigators.

J Huntingtons Dis. 2019 Jul 29. doi: 10.3233/JHD-190365. [Epub ahead of print]

PMID:
31381523
2.

The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting.

Blair IA, Farmer J, Hersch S, Larkindale J, Lynch DR, Napierala J, Napierala M, Payne RM, Subramony SH.

Future Sci OA. 2019 Jun 28;5(6):FSO398. doi: 10.2144/fsoa-2019-0026. Review.

3.

Electrocardiogram Abnormalities Suggest Aberrant Cardiac Conduction in Huntington's Disease.

Stephen CD, Hung J, Schifitto G, Hersch SM, Rosas HD.

Mov Disord Clin Pract. 2018 Apr 11;5(3):306-311. doi: 10.1002/mdc3.12596. eCollection 2018 May-Jun.

4.

Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease.

Rosas HD, Wilkens P, Salat DH, Mercaldo ND, Vangel M, Yendiki AY, Hersch SM.

Neuroimage Clin. 2018 Feb 19;20:236-242. doi: 10.1016/j.nicl.2018.01.029. eCollection 2018.

5.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

6.

The CREST-E study of creatine for Huntington disease: A randomized controlled trial.

Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD; Huntington Study Group CREST-E Investigators and Coordinators.

Neurology. 2017 Aug 8;89(6):594-601. doi: 10.1212/WNL.0000000000004209. Epub 2017 Jul 12.

7.

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.

Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4676-E4685. doi: 10.1073/pnas.1614943114. Epub 2017 May 22.

8.

LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.

Chopra V, Quinti L, Khanna P, Paganetti P, Kuhn R, Young AB, Kazantsev AG, Hersch S.

J Huntingtons Dis. 2016 Dec 15;5(4):347-355.

9.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
10.

A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, Matson W, Hersch SM.

Ann Clin Transl Neurol. 2015 Jul;2(7):756-68. doi: 10.1002/acn3.214. Epub 2015 May 28.

11.

Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.

Narayanan KL, Chopra V, Rosas HD, Malarick K, Hersch S.

Mol Neurobiol. 2016 May;53(4):2132-40. doi: 10.1007/s12035-015-9147-9. Epub 2015 May 5.

12.

Translation initiation rate determines the impact of ribosome stalling on bacterial protein synthesis.

Hersch SJ, Elgamal S, Katz A, Ibba M, Navarre WW.

J Biol Chem. 2014 Oct 10;289(41):28160-71. doi: 10.1074/jbc.M114.593277. Epub 2014 Aug 22.

13.

EF-P dependent pauses integrate proximal and distal signals during translation.

Elgamal S, Katz A, Hersch SJ, Newsom D, White P, Navarre WW, Ibba M.

PLoS Genet. 2014 Aug 21;10(8):e1004553. doi: 10.1371/journal.pgen.1004553. eCollection 2014 Aug.

14.

Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.

Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, Volitakis I, Cherny RA, Chopra V, Bush AI, Hersch S, Fox JH.

Neurobiol Dis. 2014 Nov;71:34-42. doi: 10.1016/j.nbd.2014.06.022. Epub 2014 Jul 8.

PMID:
25014023
15.

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.

Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM.

Neurology. 2014 Mar 11;82(10):850-7. doi: 10.1212/WNL.0000000000000187. Epub 2014 Feb 7.

16.

Iron accumulates in Huntington's disease neurons: protection by deferoxamine.

Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, Volitakis I, Bush AI, Hersch S, Fox JH.

PLoS One. 2013 Oct 11;8(10):e77023. doi: 10.1371/journal.pone.0077023. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/67f555f5-35b7-4468-8bab-26d518942803.

17.

HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM; Huntington Study Group PHAROS Investigators.

Neurology. 2013 Sep 24;81(13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. Epub 2013 Aug 21.

18.

Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset.

Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME.

Neurogenetics. 2013 Nov;14(3-4):173-9. doi: 10.1007/s10048-013-0364-y. Epub 2013 May 4.

19.

Divergent protein motifs direct elongation factor P-mediated translational regulation in Salmonella enterica and Escherichia coli.

Hersch SJ, Wang M, Zou SB, Moon KM, Foster LJ, Ibba M, Navarre WW.

MBio. 2013 Apr 23;4(2):e00180-13. doi: 10.1128/mBio.00180-13.

20.

A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease.

Thomas B, Matson S, Chopra V, Sun L, Sharma S, Hersch S, Rosas HD, Scherzer C, Ferrante R, Matson W.

Anal Biochem. 2013 May 15;436(2):112-20. doi: 10.1016/j.ab.2013.01.035. Epub 2013 Feb 12.

21.

(R)-β-lysine-modified elongation factor P functions in translation elongation.

Bullwinkle TJ, Zou SB, Rajkovic A, Hersch SJ, Elgamal S, Robinson N, Smil D, Bolshan Y, Navarre WW, Ibba M.

J Biol Chem. 2013 Feb 8;288(6):4416-23. doi: 10.1074/jbc.M112.438879. Epub 2012 Dec 31.

22.

The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.

Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, Cipicchio PM, Lauver MA, Choi SH, Silverman RB, Ferrante RJ, Hersch S, Kazantsev AG.

Cell Rep. 2012 Dec 27;2(6):1492-7. doi: 10.1016/j.celrep.2012.11.001. Epub 2012 Nov 29.

23.

Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.

Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME.

Hum Genet. 2012 Dec;131(12):1833-40. doi: 10.1007/s00439-012-1205-z. Epub 2012 Jul 25.

24.

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Landwehrmeyer GB; Registry Study of the European Huntington's Disease Network, Shoulson I; Huntington Study Group COHORT project, Myers RH, MacDonald ME, Gusella JF.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):404-8. Epub 2012 Jul 3.

25.

EEG neurofeedback for ADHD: double-blind sham-controlled randomized pilot feasibility trial.

Arnold LE, Lofthouse N, Hersch S, Pan X, Hurt E, Bates B, Kassouf K, Moone S, Grantier C.

J Atten Disord. 2013 Jul;17(5):410-9. doi: 10.1177/1087054712446173. Epub 2012 May 22.

26.

Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, Bush A, Fox J, Hersch SM.

Arch Neurol. 2012 Jul;69(7):887-93.

27.

Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region.

Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, MacDonald ME, Gusella JF.

Am J Hum Genet. 2012 Mar 9;90(3):434-44. doi: 10.1016/j.ajhg.2012.01.005. Epub 2012 Mar 1.

28.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.

Neurology. 2012 Mar 6;78(10):690-5. doi: 10.1212/WNL.0b013e318249f683. Epub 2012 Feb 8.

29.

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, Matson W, Kieburtz K; Huntington Study Group Pre-2CARE Investigators.

J Huntingtons Dis. 2012;1(1):65-9. doi: 10.3233/JHD-2012-120007.

30.

A review of neurofeedback treatment for pediatric ADHD.

Lofthouse N, Arnold LE, Hersch S, Hurt E, DeBeus R.

J Atten Disord. 2012 Jul;16(5):351-72. doi: 10.1177/1087054711427530. Epub 2011 Nov 16. Review.

PMID:
22090396
31.

Loss of elongation factor P disrupts bacterial outer membrane integrity.

Zou SB, Hersch SJ, Roy H, Wiggers JB, Leung AS, Buranyi S, Xie JL, Dare K, Ibba M, Navarre WW.

J Bacteriol. 2012 Jan;194(2):413-25. doi: 10.1128/JB.05864-11. Epub 2011 Nov 11. Erratum in: J Bacteriol. 2012 Aug;194(16):4484.

32.

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse.

Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H, Zheng B, Matson WR, Ferrante RJ, Rosas HD, Hersch SM, Scherzer CR.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17141-6. doi: 10.1073/pnas.1104409108. Epub 2011 Oct 3.

33.

Biomarkers to Enable the Development of Neuroprotective Therapies for Huntington’s Disease.

Hersch SM, Rosas HD.

In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 11.

34.

The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS.

Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, Chopra V, Hersch SM, Kazantsev AG.

Hum Mol Genet. 2011 Oct 15;20(20):3986-96. doi: 10.1093/hmg/ddr326. Epub 2011 Jul 26.

35.

A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.

Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM.

Mov Disord. 2011 Aug 1;26(9):1691-7. doi: 10.1002/mds.23762. Epub 2011 May 24.

36.

Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.

Fox JH, Connor T, Stiles M, Kama J, Lu Z, Dorsey K, Lieberman G, Sapp E, Cherny RA, Banks M, Volitakis I, DiFiglia M, Berezovska O, Bush AI, Hersch SM.

J Biol Chem. 2011 May 20;286(20):18320-30. doi: 10.1074/jbc.M110.199448. Epub 2011 Mar 30. Erratum in: J Biol Chem. 2011 Jul 29;286(30):27068. Liebermann, Gregory [corrected to Lieberman, Gregory].

37.

Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease.

Moscovitch-Lopatin M, Weiss A, Rosas HD, Ritch J, Doros G, Kegel KB, Difiglia M, Kuhn R, Bilbe G, Paganetti P, Hersch S.

PLoS Curr. 2010 Dec 29;2:RRN1205. doi: 10.1371/currents.RRN1205.

38.

Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count.

Weiss A, Grueninger S, Abramowski D, Giorgio FP, Lopatin MM, Rosas HD, Hersch S, Paganetti P.

Anal Biochem. 2011 Mar 15;410(2):304-6. doi: 10.1016/j.ab.2010.11.044. Epub 2010 Dec 4.

PMID:
21134349
39.

Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.

Quinti L, Chopra V, Rotili D, Valente S, Amore A, Franci G, Meade S, Valenza M, Altucci L, Maxwell MM, Cattaneo E, Hersch S, Mai A, Kazantsev A.

PLoS Curr. 2010 Sep 2;2. pii: RRN1172. doi: 10.1371/currents.RRN1172.

40.

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.

Fox JH, Connor T, Chopra V, Dorsey K, Kama JA, Bleckmann D, Betschart C, Hoyer D, Frentzel S, Difiglia M, Paganetti P, Hersch SM.

Mol Neurodegener. 2010 Jun 22;5:26. doi: 10.1186/1750-1326-5-26.

41.

Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.

Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ.

Biochim Biophys Acta. 2010 Jul-Aug;1802(7-8):673-81. doi: 10.1016/j.bbadis.2010.05.001. Epub 2010 May 9.

42.

The PTB domain of ShcA couples receptor activation to the cytoskeletal regulator IQGAP1.

Smith MJ, Hardy WR, Li GY, Goudreault M, Hersch S, Metalnikov P, Starostine A, Pawson T, Ikura M.

EMBO J. 2010 Mar 3;29(5):884-96. doi: 10.1038/emboj.2009.399. Epub 2010 Jan 14.

43.

Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry.

Ebbel EN, Leymarie N, Schiavo S, Sharma S, Gevorkian S, Hersch S, Matson WR, Costello CE.

Anal Biochem. 2010 Apr 15;399(2):152-61. doi: 10.1016/j.ab.2010.01.010. Epub 2010 Jan 13.

44.

Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection".

Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, Fischl B, Pappu V, Onorato C, Cha JH, Salat DH, Hersch SM.

Neuroimage. 2010 Feb 15;49(4):2995-3004. doi: 10.1016/j.neuroimage.2009.10.015. Epub 2009 Oct 19.

45.

Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease.

Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, Fox J, Kegel K, Klein C, Grueninger S, Hersch S, Housman D, Régulier E, Rosas HD, Stefani M, Zeitlin S, Bilbe G, Paganetti P.

Anal Biochem. 2009 Dec 1;395(1):8-15. doi: 10.1016/j.ab.2009.08.001. Epub 2009 Aug 6.

PMID:
19664996
46.

Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM.

Ann N Y Acad Sci. 2008 Dec;1147:196-205. doi: 10.1196/annals.1427.034. Review.

47.

Linking SNPs to CAG repeat length in Huntington's disease patients.

Liu W, Kennington LA, Rosas HD, Hersch S, Cha JH, Zamore PD, Aronin N.

Nat Methods. 2008 Nov;5(11):951-3. doi: 10.1038/nmeth.1261. Epub 2008 Oct 19.

48.

Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications.

Brocklebank D, Gayán J, Andresen JM, Roberts SA, Young AB, Snodgrass SR, Penney JB, Ramos-Arroyo MA, Cha JJ, Rosas HD, Hersch SM, Feigin A, Cherny SS, Wexler NS, Housman DE, Cardon LR; International-Venezuela Collaborative Research Group.

Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):425-9. doi: 10.1002/ajmg.b.30826.

49.

Metabolite identification using a nanoelectrospray LC-EC-array-MS integrated system.

Schiavo S, Ebbel E, Sharma S, Matson W, Kristal BS, Hersch S, Vouros P.

Anal Chem. 2008 Aug 1;80(15):5912-23. doi: 10.1021/ac800507y. Epub 2008 Jun 25.

50.

Neuroprotection for Huntington's disease: ready, set, slow.

Hersch SM, Rosas HD.

Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Review.

Supplemental Content

Loading ...
Support Center